GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

GE HealthCare agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. The deal is expected to close in the first half of 2027, subject to closing conditions including regulatory approvals; SOFIE would then join GE HealthCare’s PDx segment.

Analysis

The strategic value is less about the acquired contract-manufacturing revenue than about securing a constrained, time-sensitive input to GE HealthCare’s PET ecosystem. More dependable radiopharmaceutical production could improve scanner utilization and customer retention, while giving GEHC a closer view of demand across imaging and tracer supply. The second-order risk cuts both ways: if SOFIE serves external drug developers or competing imaging platforms, customers may question neutrality after the change of ownership; limiting that business could dilute the value of the acquisition.

This is a long-dated execution story, not a near-term earnings catalyst: closing is not expected until 1H27 and is contingent on approvals. The cash purchase price is material enough to scrutinize against SOFIE’s revenue, capacity, utilization, customer concentration and required expansion spending, none of which is provided. Without those data, neither accretion nor an attractive return on invested capital is established. Competitors such as Siemens Healthineers and radiopharmaceutical suppliers may face a stronger integrated rival, but only if GEHC can add reliable capacity rather than merely change ownership of existing output.

Contrarian view: the market may over-credit vertical integration before evidence that supply is a binding constraint or that GEHC can capture economics beyond the manufacturing fee. Conversely, the longer-run option value may be underappreciated if PET tracer access becomes a differentiator in customer purchasing decisions. Near-term price action should be modest absent disclosed financial contribution or a change in guidance.

Key Decisions for Investors

• Do not chase GEHC solely on the announcement; treat it as a strategic watch item rather than a quantified earnings catalyst.
• Before adding exposure, verify SOFIE’s revenue, margins, customer mix, production capacity/utilization, expansion capex, and whether existing third-party customers can continue to source independently after closing.
• Monitor GEHC’s PDx guidance, acquisition-return commentary and regulatory milestones through 1H27. A material deal delay, customer losses, or evidence of substantial incremental investment without corresponding capacity growth would weaken the thesis.
• Relative-value watch: compare GEHC’s PET-related execution and guidance with Siemens Healthineers and relevant radiopharmaceutical suppliers; consider a pair only if subsequent disclosures show a measurable GEHC supply or utilization advantage.